We are live on
!
Find out more
YIH
Y-Intercept (HK) Portfolio holdings
AUM
$5.05B
1-Year Est. Return
17.89%
This Fund
S&P 500
This Quarter
Est. Return
+8.14%
1 Year Est. Return
+17.89%
3 Year Est. Return
+34.37%
5 Year Est. Return
+20.59%
10 Year Est. Return
–
AUM
$4.09B
AUM Growth
+$2.61B
(+177%)
Cap. Flow
+$2.46B
Cap. Flow
% of AUM
60.1%
Top 10 Holdings %
Top 10 Hldgs %
6.33%
Holding
2,105
New
963
Increased
487
Reduced
137
Closed
518
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$37.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$35.1M |
| 3 |
T-Mobile US
TMUS
|
+$30.4M |
| 4 |
Nu Holdings
NU
|
+$27.8M |
| 5 |
Consolidated Edison
ED
|
+$26.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arista Networks
ANET
|
+$17M |
| 2 |
Marvell Technology
MRVL
|
+$16.2M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$16.1M |
| 4 |
ServiceNow
NOW
|
+$13.3M |
| 5 |
Walmart Inc
WMT
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.87% |
| 2 | Industrials | 14.69% |
| 3 | Financials | 14.36% |
| 4 | Healthcare | 12.68% |
| 5 | Consumer Discretionary | 12.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1551
C4 Therapeutics
CCCC
$389M
| $75.1K | ﹤0.01% |
+52,521
| New | +$76.4K |
|
1552
Blink Charging
BLNK
$67.5M
| $64K | ﹤0.01% |
+68,042
| New | +$54.3K |
|
1553
JetBlue
JBLU
$2.13B
| $62.5K | ﹤0.01% |
+14,774
| New | +$66.1K |
|
|
BOLD
1554
Boundless Bio
BOLD
$55.7M
| $55.8K | ﹤0.01% |
+55,242
| New | +$73.4K |
|
|
DDL
1555
Dingdong
DDL
$525M
| $54.2K | ﹤0.01% |
+26,818
| New | +$60.6K |
|
1556
Ovid Therapeutics
OVID
$427M
| $52.9K | ﹤0.01% |
+160,306
| New | +$48.3K |
|
1557
Aemetis
AMTX
$99.2M
| $51K | ﹤0.01% |
+20,556
| New | +$34.8K |
|
1558
Century Therapeutics
IPSC
$364M
| $50.3K | ﹤0.01% |
+89,975
| New | +$48.3K |
|
1559
JELD-WEN Holding
JELD
$110M
| $49K | ﹤0.01% |
+12,497
| New | +$55.7K |
|
|
ARTV
1560
Artiva Biotherapeutics
ARTV
$487M
| $47.7K | ﹤0.01% |
+31,567
| New | +$66.3K |
|
1561
Sutro Biopharma
STRO
$386M
| $47.5K | ﹤0.01% |
+6,659
| New | +$54.5K |
|
|
GBIO
1562
DELISTED
Generation Bio
GBIO
| $47.4K | ﹤0.01% |
+14,819
| New | +$57.1K |
|
|
ADVM
1563
DELISTED
Adverum Biotechnologies
ADVM
| $45.4K | ﹤0.01% |
+21,122
| New | +$59.1K |
|
|
FSP
1564
Franklin Street Properties
FSP
$49.8M
| $43.2K | ﹤0.01% |
+26,332
| New | +$43.9K |
|
1565
Cardlytics
CDLX
$22.2M
| $42.4K | ﹤0.01% |
+2,579
| New | +$44.5K |
|
1566
Skye Bioscience
SKYE
$21.6M
| $42K | ﹤0.01% |
+10,046
| New | +$20.8K |
|
1567
Neumora Therapeutics
NMRA
$306M
| $41.9K | ﹤0.01% |
+57,072
| New | +$43.2K |
|
1568
SES AI
SES
$187M
| $41.3K | ﹤0.01% |
+46,493
| New | +$39K |
|
1569
Prelude Therapeutics
PRLD
$375M
| $38.7K | ﹤0.01% |
+47,788
| New | +$41.4K |
|
1570
Zentalis Pharmaceuticals
ZNTL
$332M
| $38K | ﹤0.01% |
+32,740
| New | +$43.2K |
|
1571
Kaltura
KLTR
$209M
| $37.9K | ﹤0.01% |
+18,873
| New | +$39.1K |
|
1572
FibroBiologics
FBLG
$3.98M
| $37K | ﹤0.01% |
+2,977
| New | +$53.7K |
|
1573
MacroGenics
MGNX
$233M
| $36.2K | ﹤0.01% |
+29,945
| New | +$43.4K |
|
1574
Black Diamond Therapeutics
BDTX
$95.1M
| $36K | ﹤0.01% |
+14,521
| New | +$28K |
|
|
ZYXI
1575
DELISTED
Zynex
ZYXI
| $35.8K | ﹤0.01% |
+13,873
| New | +$31.4K |
|
Similar funds
HSA
O
LFG
JIM
CTC
NL
BPWM
VT
Y-Intercept (HK)'s Q2 2025 Portfolio in Review
As of Q2 2025, Y-Intercept (HK) held 2,105 positions worth $4.09B, up 177% from $1.48B the previous quarter. Its ten largest holdings account for 6.3% of the portfolio.
Y-Intercept (HK) deployed $2.46B of net new capital in Q2 2025, opening 963 new positions and adding to 487 existing holdings. Its largest new stake was Nu Holdings: 2,319,643 shares worth $31.8M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, down from 19% a quarter earlier, followed by Industrials and Financials.
On the sell side, the largest reduction was Novo Nordisk, an estimated $16.1M trimmed.
- Y-Intercept (HK)'s largest Q2 2025 buy was Nu Holdings: 2,319,643 shares worth $31.8M.
- Y-Intercept (HK) added most to UnitedHealth in Q2 2025, an estimated $37.8M increase.
- Y-Intercept (HK)'s biggest Q2 2025 reduction was Novo Nordisk, cutting an estimated $16.1M.
- Y-Intercept (HK) fully exited Arista Networks in Q2 2025, selling an estimated $17M.
- Y-Intercept (HK)'s ten largest holdings make up 6.3% of its $4.09B portfolio in Q2 2025.
- Y-Intercept (HK) opened 963 new positions and closed 518 in Q2 2025.
- Y-Intercept (HK)'s portfolio value rose 177% quarter-over-quarter to $4.09B.
Based on Y-Intercept (HK)'s 13F filing for Q2 2025, filed 1 Aug 2025.